Skip to main content
Top
Published in: BMC Immunology 1/2013

Open Access 01-12-2013 | Research article

Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort

Authors: Damalie Nakanjako, Isaac Ssewanyana, Rose Nabatanzi, Agnes Kiragga, Moses R Kamya, Huyen Cao, Harriet Mayanja-Kizza

Published in: BMC Immunology | Issue 1/2013

Login to get access

Abstract

Background

Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proliferation among suboptimal responders and its correlation with CD4 T-cell activation.

Methods

The magnitude of CD4 increase (difference between absolute CD4 counts at baseline and absolute CD4 counts at 4 years of ART) was grouped into 4 quartiles for the 211 patients with sustained HIV-RNA viral suppression. Cases of ‘Suboptimal immune responders’ included patients within the lowest quartile [Median CD4 increase 165 (Range −43-298) cells/μl; n=52] and a comparison group of ‘Optimal immune responders’ was defined as patients within the highest quartile of CD4 increase [Median CD4 increase 528 (Range 417–878) cells/μl; n=52]. Frozen PBMC were thawed and analysed from a convenient sample of 39 suboptimal responders and 48 optimal responders after 4 years of suppressive antiretroviral therapy. T-cell activation was measured by proportions of T-cells expressing surface marker CD38 and HLADR (CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells). T-cell proliferation was determined by the extent of carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution on culture day 5 of PBMCs in the presence of antigen (SEB, PPD, CMVpp65, GagA and GagD). Samples were analyzed on a FACS Calibur flow cytometer and flow data was analyzed using FlowJo and GraphPad.

Results

Overall, CD4 T-cell proliferation on stimulation with SEB, PPD, CMVpp65, Gag A and Gag D.antigens, was lower among suboptimal than optimal responders; this was significant for SEB (CD4+ p=0.003; CD8+ p=0.048) and PPD antigens (CD8+ p=0.038). Among suboptimal responders, T-cell proliferation decreased with increasing immune activation (Negative correlation; slope = −0.13±−0.11) but not among optimal responders.

Conclusion

T-cell immune activation and exhaustion were associated with poor proliferation among suboptimal responders to HAART despite sustained viral suppression. We recommend studies to further understand the mechanisms leading to impaired T-cell function among suboptimal responders as well as the potential role of immune modulation in optimizing CD4 count and functional recovery after HAART.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997, 278 (5342): 1447-1450. 10.1126/science.278.5342.1447.CrossRefPubMed Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997, 278 (5342): 1447-1450. 10.1126/science.278.5342.1447.CrossRefPubMed
2.
go back to reference Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL: Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol. 2003, 77 (20): 10900-10909. 10.1128/JVI.77.20.10900-10909.2003.PubMedCentralCrossRefPubMed Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL: Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol. 2003, 77 (20): 10900-10909. 10.1128/JVI.77.20.10900-10909.2003.PubMedCentralCrossRefPubMed
3.
go back to reference Glencross DK, Janossy G, Coetzee LM, Lawrie D, Scott LE, Sanne I, McIntyre JA, Stevens W: CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008, 74 (Suppl 1): S131-140.CrossRefPubMed Glencross DK, Janossy G, Coetzee LM, Lawrie D, Scott LE, Sanne I, McIntyre JA, Stevens W: CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008, 74 (Suppl 1): S131-140.CrossRefPubMed
4.
go back to reference Guihot A, Bourgarit A, Carcelain G, Autran B: Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011, 32 (3): 131-137. 10.1016/j.it.2010.12.002.CrossRefPubMed Guihot A, Bourgarit A, Carcelain G, Autran B: Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011, 32 (3): 131-137. 10.1016/j.it.2010.12.002.CrossRefPubMed
5.
go back to reference Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005, 41 (3): 361-372. 10.1086/431484.CrossRefPubMed Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005, 41 (3): 361-372. 10.1086/431484.CrossRefPubMed
6.
go back to reference Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ: Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008, 5: 23-10.1186/1742-6405-5-23.PubMedCentralCrossRefPubMed Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ: Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008, 5: 23-10.1186/1742-6405-5-23.PubMedCentralCrossRefPubMed
7.
go back to reference Nakanjako D, Colebunders R, Coutinho AG, Kamya MR: Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev. 2009, 11 (4): 179-189.PubMed Nakanjako D, Colebunders R, Coutinho AG, Kamya MR: Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev. 2009, 11 (4): 179-189.PubMed
8.
go back to reference Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol. 2002, 102 (2): 154-161. 10.1006/clim.2001.5164.CrossRefPubMed Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol. 2002, 102 (2): 154-161. 10.1006/clim.2001.5164.CrossRefPubMed
9.
go back to reference Blankson JN, Gallant JE, Siliciano RF: Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis. 2001, 183 (4): 657-661. 10.1086/318545.CrossRefPubMed Blankson JN, Gallant JE, Siliciano RF: Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis. 2001, 183 (4): 657-661. 10.1086/318545.CrossRefPubMed
10.
go back to reference Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M, Barsoum S, Vanderhoeven J: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002, 186 (5): 634-643. 10.1086/342559.CrossRefPubMed Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M, Barsoum S, Vanderhoeven J: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002, 186 (5): 634-643. 10.1086/342559.CrossRefPubMed
11.
go back to reference Palmer BE, Boritz E, Blyveis N, Wilson CC: Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol. 2002, 76 (12): 5925-5936. 10.1128/JVI.76.12.5925-5936.2002.PubMedCentralCrossRefPubMed Palmer BE, Boritz E, Blyveis N, Wilson CC: Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol. 2002, 76 (12): 5925-5936. 10.1128/JVI.76.12.5925-5936.2002.PubMedCentralCrossRefPubMed
12.
go back to reference Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G: The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009, 48 (3): 328-337.CrossRefPubMed Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G: The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009, 48 (3): 328-337.CrossRefPubMed
13.
go back to reference Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF: Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007, 46 (2): 187-193. 10.1097/QAI.0b013e31814278c0.CrossRefPubMed Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF: Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007, 46 (2): 187-193. 10.1097/QAI.0b013e31814278c0.CrossRefPubMed
14.
go back to reference Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S: Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001, 15 (14): 1749-1756. 10.1097/00002030-200109280-00002.CrossRefPubMed Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S: Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001, 15 (14): 1749-1756. 10.1097/00002030-200109280-00002.CrossRefPubMed
15.
go back to reference Kityo C, Bousheri S, Akao J, Ssali F, Byaruhanga R, Ssewanyana I, Muloma P, Myalo S, Magala R, Lu Y: Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. Vaccine. 2011, 29 (8): 1617-1623. 10.1016/j.vaccine.2010.12.066.PubMedCentralCrossRefPubMed Kityo C, Bousheri S, Akao J, Ssali F, Byaruhanga R, Ssewanyana I, Muloma P, Myalo S, Magala R, Lu Y: Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. Vaccine. 2011, 29 (8): 1617-1623. 10.1016/j.vaccine.2010.12.066.PubMedCentralCrossRefPubMed
16.
go back to reference Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM: HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007, 109 (8): 3351-3359. 10.1182/blood-2006-07-034785.PubMedCentralCrossRefPubMed Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM: HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007, 109 (8): 3351-3359. 10.1182/blood-2006-07-034785.PubMedCentralCrossRefPubMed
17.
go back to reference Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A: Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol. 2003, 170 (8): 4260-4266.CrossRefPubMed Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A: Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol. 2003, 170 (8): 4260-4266.CrossRefPubMed
18.
go back to reference Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H: High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011, 11: 43-10.1186/1471-2334-11-43.PubMedCentralCrossRefPubMed Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H: High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011, 11: 43-10.1186/1471-2334-11-43.PubMedCentralCrossRefPubMed
19.
go back to reference Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, Estes JD, Burton GF, Silvestri G, Lifson JD: Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest. 2011, 121 (3): 998-1008. 10.1172/JCI45157.PubMedCentralCrossRefPubMed Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, Estes JD, Burton GF, Silvestri G, Lifson JD: Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest. 2011, 121 (3): 998-1008. 10.1172/JCI45157.PubMedCentralCrossRefPubMed
20.
go back to reference Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, Haase AT: Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012, 8 (1): e1002437-10.1371/journal.ppat.1002437.PubMedCentralCrossRefPubMed Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, Haase AT: Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012, 8 (1): e1002437-10.1371/journal.ppat.1002437.PubMedCentralCrossRefPubMed
21.
go back to reference Lane PJ, Gaspal FM, McConnell FM, Kim MY, Anderson G, Withers DR: Lymphoid tissue inducer cells: innate cells critical for CD4+ T cell memory responses?. Ann N Y Acad Sci. 2012, 1247: 1-15. 10.1111/j.1749-6632.2011.06284.x.CrossRefPubMed Lane PJ, Gaspal FM, McConnell FM, Kim MY, Anderson G, Withers DR: Lymphoid tissue inducer cells: innate cells critical for CD4+ T cell memory responses?. Ann N Y Acad Sci. 2012, 1247: 1-15. 10.1111/j.1749-6632.2011.06284.x.CrossRefPubMed
22.
go back to reference Moodley K, Coetzee LM, Glencross DK: Decentralised CD38 activation monitoring: aspects of practical implementation and standardisation. J Immunol Methods. 2012, 378 (1–2): 121-127.CrossRefPubMed Moodley K, Coetzee LM, Glencross DK: Decentralised CD38 activation monitoring: aspects of practical implementation and standardisation. J Immunol Methods. 2012, 378 (1–2): 121-127.CrossRefPubMed
23.
go back to reference Negredo E, Massanella M, Puig J, Perez-Alvarez N, Gallego-Escuredo JM, Villarroya J, Villarroya F, Molto J, Santos JR, Clotet B: Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010, 50 (9): 1300-1308. 10.1086/651689.CrossRefPubMed Negredo E, Massanella M, Puig J, Perez-Alvarez N, Gallego-Escuredo JM, Villarroya J, Villarroya F, Molto J, Santos JR, Clotet B: Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010, 50 (9): 1300-1308. 10.1086/651689.CrossRefPubMed
24.
go back to reference Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD: Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006, 20 (8): 1141-1150. 10.1097/01.aids.0000226954.95094.39.CrossRefPubMed Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD: Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006, 20 (8): 1141-1150. 10.1097/01.aids.0000226954.95094.39.CrossRefPubMed
25.
go back to reference Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44 (3): 441-446. 10.1086/510746.CrossRefPubMed Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44 (3): 441-446. 10.1086/510746.CrossRefPubMed
26.
go back to reference Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaied F, Leport C, Raffi F: Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007, 8 (3): 156-163. 10.1111/j.1468-1293.2007.00446.x.CrossRefPubMed Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaied F, Leport C, Raffi F: Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007, 8 (3): 156-163. 10.1111/j.1468-1293.2007.00446.x.CrossRefPubMed
27.
go back to reference Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004, 200 (6): 749-759. 10.1084/jem.20040874.PubMedCentralCrossRefPubMed Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004, 200 (6): 749-759. 10.1084/jem.20040874.PubMedCentralCrossRefPubMed
28.
go back to reference Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ: Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013, 368 (3): 218-230. 10.1056/NEJMoa1110187.PubMedCentralCrossRefPubMed Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ: Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013, 368 (3): 218-230. 10.1056/NEJMoa1110187.PubMedCentralCrossRefPubMed
29.
go back to reference Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, Amoura Z, Katlama C, Autran B: Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005, 201 (12): 1999-2010. 10.1084/jem.20042408.PubMedCentralCrossRefPubMed Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, Amoura Z, Katlama C, Autran B: Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005, 201 (12): 1999-2010. 10.1084/jem.20042408.PubMedCentralCrossRefPubMed
31.
go back to reference Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR: VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for AntiViral-HyperActivation limiting therapeutics. PLoS One. 2012, 7 (10): e47485-10.1371/journal.pone.0047485.PubMedCentralCrossRefPubMed Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR: VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for AntiViral-HyperActivation limiting therapeutics. PLoS One. 2012, 7 (10): e47485-10.1371/journal.pone.0047485.PubMedCentralCrossRefPubMed
32.
go back to reference Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D: Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011, 118 (12): 3263-3272. 10.1182/blood-2011-01-329060.CrossRefPubMed Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D: Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011, 118 (12): 3263-3272. 10.1182/blood-2011-01-329060.CrossRefPubMed
Metadata
Title
Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
Authors
Damalie Nakanjako
Isaac Ssewanyana
Rose Nabatanzi
Agnes Kiragga
Moses R Kamya
Huyen Cao
Harriet Mayanja-Kizza
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2013
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-14-26

Other articles of this Issue 1/2013

BMC Immunology 1/2013 Go to the issue